Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
NASDAQ:XNCR

Xencor - XNCR Stock Forecast, Price & News

$28.17
-0.37 (-1.30%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$27.96
$28.75
50-Day Range
$24.62
$30.51
52-Week Range
$19.35
$42.30
Volume
329,870 shs
Average Volume
344,843 shs
Market Capitalization
$1.69 billion
P/E Ratio
58.69
Dividend Yield
N/A
Price Target
$48.89

Xencor MarketRank™ Forecast

Analyst Rating
Buy
3.11 Rating Score
Upside/​Downside
73.5% Upside
$48.89 Price Target
Short Interest
Bearish
6.84% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
0.80mentions of Xencor in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.65) to ($2.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

508th out of 1,040 stocks

Pharmaceutical Preparations Industry

242nd out of 509 stocks

XNCR stock logo

About Xencor (NASDAQ:XNCR) Stock

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

XNCR Stock News Headlines

Xencor (XNCR) Upgraded to Buy: Here's What You Should Know
THE BEST BLACK FRIDAY DEAL YET
This Black Friday, you can save 95% off of a 1-year membership to Brad Thomas’s Intelligent Income Investor. This service is geared toward helping you collect the safest dividend income in the market. It all starts with Brad’s “SWAN” portfolio, of the 10 best companies to own through any market.
Xencor Earnings Preview
See how to make money instead of spending it on Black Friday with this offer
Ph.D. Economist and Investor Nomi Prins is releasing details on her next stunning prediction… It involves “liquid energy” that is promising to trigger an energy revolution 117x bigger than all of the hottest tech trends combined. Even the world’s richest billionaires are investing in the tiny company behind it. And today, you can get in on this cutting-edge financial research at an incredible price tailor-made for Black Friday.
Xencor Inc
See More Headlines
Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

XNCR Company Calendar

Last Earnings
11/08/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XNCR
Employees
254
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.89
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+73.5%
Consensus Rating
Buy
Rating Score (0-4)
3.11
Research Coverage
9 Analysts

Profitability

Net Income
$82.63 million
Pretax Margin
10.44%

Debt

Sales & Book Value

Annual Sales
$275.11 million
Cash Flow
$1.59 per share
Book Value
$12.54 per share

Miscellaneous

Free Float
57,389,000
Market Cap
$1.69 billion
Optionable
Optionable
Beta
0.62

Key Executives

  • Dr. Bassil I. Dahiyat Ph.D. (Age 52)
    Co-Founder, CEO, Pres & Director
    Comp: $1.08M
  • Mr. John J. Kuch (Age 63)
    Sr. VP & CFO
    Comp: $648.03k
  • Dr. John R. Desjarlais (Age 58)
    Sr. VP of Research & Chief Scientific Officer
    Comp: $725.03k
  • Ms. Celia E. Eckert J.D. (Age 49)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $600.93k
  • Dr. Allen S. Yang M.D. (Age 54)
    Ph.D., Sr. VP & Chief Medical Officer
    Comp: $748.13k
  • Mr. Charles Liles
    Associate Director and Head of Corp. Communications & Investor Relations
  • Ms. Jennifer Sandoz
    VP of HR
  • Dr. Jeremy Grunstein Ph.D.
    Sr. VP of Bus. Devel.
  • Mr. Kirk Rosemark RAC (Age 57)
    Sr. VP of Regulatory Affairs & Quality Assurance













XNCR Stock - Frequently Asked Questions

Should I buy or sell Xencor stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XNCR shares.
View XNCR analyst ratings
or view top-rated stocks.

What is Xencor's stock price forecast for 2023?

9 Wall Street research analysts have issued 12-month price targets for Xencor's shares. Their XNCR share price forecasts range from $36.00 to $60.00. On average, they predict the company's stock price to reach $48.89 in the next year. This suggests a possible upside of 71.3% from the stock's current price.
View analysts price targets for XNCR
or view top-rated stocks among Wall Street analysts.

How have XNCR shares performed in 2022?

Xencor's stock was trading at $40.12 at the start of the year. Since then, XNCR shares have decreased by 28.9% and is now trading at $28.54.
View the best growth stocks for 2022 here
.

When is Xencor's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our XNCR earnings forecast
.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) announced its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.06. The biopharmaceutical company earned $19.68 million during the quarter, compared to analysts' expectations of $17.63 million. Xencor had a trailing twelve-month return on equity of 4.04% and a net margin of 10.07%. During the same period in the previous year, the business earned ($0.22) EPS.

What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Who are Xencor's major shareholders?

Xencor's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.70%), Vanguard Group Inc. (10.95%), Primecap Management Co. CA (9.50%), State Street Corp (5.43%), Price T Rowe Associates Inc. MD (5.36%) and Dimensional Fund Advisors LP (1.95%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert, John J Kuch, John S Stafford III and Ronin Capital, Llc.
View institutional ownership trends
.

How do I buy shares of Xencor?

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $28.54.

How much money does Xencor make?

Xencor (NASDAQ:XNCR) has a market capitalization of $1.71 billion and generates $275.11 million in revenue each year. The biopharmaceutical company earns $82.63 million in net income (profit) each year or $0.48 on an earnings per share basis.

How many employees does Xencor have?

The company employs 254 workers across the globe.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for the company is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at investors@xencor.com, or via fax at 626-305-0350.

This page (NASDAQ:XNCR) was last updated on 11/28/2022 by MarketBeat.com Staff